Cargando…
Surveillance of spontaneous breast cancer metastasis by TRAIL-expressing CD34(+) cells in a xenograft model
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), delivered as a membrane-bound molecule expressed on the surface of adenovirus-transduced CD34(+) cells (CD34-TRAIL(+)), was analyzed for its apoptotic activity in vitro on 12 breast cancer cell lines representing estrogen receptor-posi...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3483102/ https://www.ncbi.nlm.nih.gov/pubmed/23053664 http://dx.doi.org/10.1007/s10549-012-2281-4 |
_version_ | 1782247941776343040 |
---|---|
author | Rossini, Anna Giussani, Marta Giacomini, Arianna Guarnotta, Carla Tagliabue, Elda Balsari, Andrea |
author_facet | Rossini, Anna Giussani, Marta Giacomini, Arianna Guarnotta, Carla Tagliabue, Elda Balsari, Andrea |
author_sort | Rossini, Anna |
collection | PubMed |
description | Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), delivered as a membrane-bound molecule expressed on the surface of adenovirus-transduced CD34(+) cells (CD34-TRAIL(+)), was analyzed for its apoptotic activity in vitro on 12 breast cancer cell lines representing estrogen receptor-positive, HER2(+) and triple-negative (TN) subtypes and for its effect on tumor growth, vascularization, necrosis, and lung metastasis incidence in NOD/SCID mice xenografted with the TN breast cancer line MDA-MB-231. Mesenchymal TN cell lines, which are the richest in putative tumor stem cells among the different breast cancer cell subtypes, were the most susceptible to apoptosis induced by CD34-TRAIL(+) cells. Indeed, tumor cell “stemness”, assessed based on the proportion of CD44(+)/CD24(−/low) cells, was significantly correlated with susceptibility to TRAIL. Moreover, in vitro cytotoxicity experiments showed that CD34-TRAIL(+) cells selectively targeted CD44(+)/CD24(−/low) cells. Although in vivo treatment with CD34-TRAIL(+) cells did not lead to tumor growth inhibition, treated mice revealed significantly larger areas of necrosis associated with damage of tumor vasculature than did control mice. Moreover, lungs from MDA-MD-231 tumor-bearing mice were completely free of metastases at 12 days after the last injection of CD34-TRAIL(+) cells, whereas metastases were present in all control mouse lungs. An anti-metastatic effect of CD34-TRAIL(+) cells was also observed in a model of experimental lung metastases. The correlation between in vitro susceptibility to membrane-bound TRAIL and tumor stem cell content, together with CD34-TRAIL(+) cell-induced inhibition of the metastatic process, points to the selective targeting of cancer stem cells by CD34-armed cells and the potential value of such cells in eradicating tumor stem cells before the onset of overt metastases. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10549-012-2281-4) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-3483102 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-34831022012-11-05 Surveillance of spontaneous breast cancer metastasis by TRAIL-expressing CD34(+) cells in a xenograft model Rossini, Anna Giussani, Marta Giacomini, Arianna Guarnotta, Carla Tagliabue, Elda Balsari, Andrea Breast Cancer Res Treat Preclinical Study Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), delivered as a membrane-bound molecule expressed on the surface of adenovirus-transduced CD34(+) cells (CD34-TRAIL(+)), was analyzed for its apoptotic activity in vitro on 12 breast cancer cell lines representing estrogen receptor-positive, HER2(+) and triple-negative (TN) subtypes and for its effect on tumor growth, vascularization, necrosis, and lung metastasis incidence in NOD/SCID mice xenografted with the TN breast cancer line MDA-MB-231. Mesenchymal TN cell lines, which are the richest in putative tumor stem cells among the different breast cancer cell subtypes, were the most susceptible to apoptosis induced by CD34-TRAIL(+) cells. Indeed, tumor cell “stemness”, assessed based on the proportion of CD44(+)/CD24(−/low) cells, was significantly correlated with susceptibility to TRAIL. Moreover, in vitro cytotoxicity experiments showed that CD34-TRAIL(+) cells selectively targeted CD44(+)/CD24(−/low) cells. Although in vivo treatment with CD34-TRAIL(+) cells did not lead to tumor growth inhibition, treated mice revealed significantly larger areas of necrosis associated with damage of tumor vasculature than did control mice. Moreover, lungs from MDA-MD-231 tumor-bearing mice were completely free of metastases at 12 days after the last injection of CD34-TRAIL(+) cells, whereas metastases were present in all control mouse lungs. An anti-metastatic effect of CD34-TRAIL(+) cells was also observed in a model of experimental lung metastases. The correlation between in vitro susceptibility to membrane-bound TRAIL and tumor stem cell content, together with CD34-TRAIL(+) cell-induced inhibition of the metastatic process, points to the selective targeting of cancer stem cells by CD34-armed cells and the potential value of such cells in eradicating tumor stem cells before the onset of overt metastases. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10549-012-2281-4) contains supplementary material, which is available to authorized users. Springer US 2012-10-11 2012 /pmc/articles/PMC3483102/ /pubmed/23053664 http://dx.doi.org/10.1007/s10549-012-2281-4 Text en © The Author(s) 2012 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Preclinical Study Rossini, Anna Giussani, Marta Giacomini, Arianna Guarnotta, Carla Tagliabue, Elda Balsari, Andrea Surveillance of spontaneous breast cancer metastasis by TRAIL-expressing CD34(+) cells in a xenograft model |
title | Surveillance of spontaneous breast cancer metastasis by TRAIL-expressing CD34(+) cells in a xenograft model |
title_full | Surveillance of spontaneous breast cancer metastasis by TRAIL-expressing CD34(+) cells in a xenograft model |
title_fullStr | Surveillance of spontaneous breast cancer metastasis by TRAIL-expressing CD34(+) cells in a xenograft model |
title_full_unstemmed | Surveillance of spontaneous breast cancer metastasis by TRAIL-expressing CD34(+) cells in a xenograft model |
title_short | Surveillance of spontaneous breast cancer metastasis by TRAIL-expressing CD34(+) cells in a xenograft model |
title_sort | surveillance of spontaneous breast cancer metastasis by trail-expressing cd34(+) cells in a xenograft model |
topic | Preclinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3483102/ https://www.ncbi.nlm.nih.gov/pubmed/23053664 http://dx.doi.org/10.1007/s10549-012-2281-4 |
work_keys_str_mv | AT rossinianna surveillanceofspontaneousbreastcancermetastasisbytrailexpressingcd34cellsinaxenograftmodel AT giussanimarta surveillanceofspontaneousbreastcancermetastasisbytrailexpressingcd34cellsinaxenograftmodel AT giacominiarianna surveillanceofspontaneousbreastcancermetastasisbytrailexpressingcd34cellsinaxenograftmodel AT guarnottacarla surveillanceofspontaneousbreastcancermetastasisbytrailexpressingcd34cellsinaxenograftmodel AT tagliabueelda surveillanceofspontaneousbreastcancermetastasisbytrailexpressingcd34cellsinaxenograftmodel AT balsariandrea surveillanceofspontaneousbreastcancermetastasisbytrailexpressingcd34cellsinaxenograftmodel |